US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
92.83
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates
↗
May 05, 2026
Via
Chartmill
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
May 05, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
May 04, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
May 01, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 09, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Q4 Revenue Beat and Narrows Loss
↗
February 26, 2026
Via
Chartmill
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March
↗
January 09, 2026
Via
Stocktwits
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...
Via
MarketMinute
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...
Via
Finterra
Topics
Economy
Intellectual Property
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...
Via
MarketMinute
Topics
Intellectual Property
Rhythm Pharmaceuticals Announces Changes to Board of Directors
April 03, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Is This Weight Loss Drug Stock a Buy After a New Approval?
↗
March 31, 2026
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
Via
The Motley Fool
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
March 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
March 19, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
March 16, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
↗
March 04, 2026
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
↗
March 04, 2026
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Via
The Motley Fool
Topics
Regulatory Compliance
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
March 01, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharma (RYTM) Earnings Call Transcript
↗
February 26, 2026
Rhythm Pharma (RYTM) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 26, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
↗
February 22, 2026
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
↗
February 22, 2026
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Via
The Motley Fool
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
↗
February 22, 2026
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Via
The Motley Fool
Topics
Regulatory Compliance
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
↗
February 22, 2026
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Via
The Motley Fool
Topics
Regulatory Compliance
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
February 17, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 3 Stocks Will Crush the Market in 2026
↗
February 16, 2026
These stocks all have catalysts on the way that could provide great news for investors.
Via
The Motley Fool
Topics
Artificial Intelligence
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
February 05, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
This High-Flying Growth Stock Is Hiding in Plain Sight
↗
February 02, 2026
This biotech stock is flying under the radar for many investors, but Wall Street loves it.
Via
The Motley Fool
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
January 09, 2026
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
December 30, 2025
As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
